Abstract
Tumour necrosis factor-alpha (TNF-α) inhibitors represent an important treatment advance for a number of inflammatory conditions, including inflammatory bowel disease. Since their introduction in 1999, it has become clear that some biological therapies may be associated with an increased risk for bacterial infections. Herein we present the first case of septic arthritis and spine empyema, caused by S. aureus, in a 63 year-old patient with ulcerative colitis, who was under treatment with Infliximab and with 40mg per day of prednisolone.
Copyright © 2009 European Crohn's and Colitis Organisation. All rights reserved.
MeSH terms
-
Anti-Inflammatory Agents / adverse effects*
-
Antibodies, Monoclonal / adverse effects*
-
Arthritis, Infectious / etiology*
-
Colitis, Ulcerative / drug therapy*
-
Colitis, Ulcerative / immunology
-
Colitis, Ulcerative / microbiology*
-
Empyema / etiology*
-
Female
-
Humans
-
Immunosuppression Therapy / adverse effects*
-
Infliximab
-
Lumbar Vertebrae / microbiology
-
Middle Aged
-
Shoulder Joint / microbiology
-
Spondylitis / etiology*
-
Staphylococcal Infections / etiology*
-
Staphylococcus aureus / isolation & purification
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal
-
Tumor Necrosis Factor-alpha
-
Infliximab